keyword
MENU ▼
Read by QxMD icon Read
search

Small bowl tumors

keyword
https://www.readbyqxmd.com/read/29668359/laparoscopic-total-mesorectal-excision-following-transanal-endoscopic-microsurgery-for-rectal-cancer
#1
Nidal Issa, Yaniv Fenig, Rachel Gingold-Belfer, Muhammad Khatib, Wisam Khoury, Lea Wolfson, Hemda Schmilovitz-Weiss
BACKGROUND: Patients' selection for transanal endoscopic microsurgery (TEM) depends on diagnostic modalities; however, there are still some limitations in the preoperative diagnosis of rectal lesions, and in some reports, up to third of the adenomas resected by TEM were found to be adenocarcinoma; therefore, salvage radical resection (RR) remains necessary for achieving oncological resection. Salvage RR may encounter some technical problems as the violation of the mesorectum and the scar formation...
April 18, 2018: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/29615459/genetic-analysis-of-779-advanced-differentiated-and-anaplastic-thyroid-cancers
#2
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan, Rebecca E Schweppe, Lauren Fishbein, Jeffrey S Ross, Bryan R Haugen, Daniel W Bowles
Purpose: To define the genetic landscape of advanced differentiated and anaplastic thyroid cancer (ATC) and identify genetic alterations of potential diagnostic, prognostic, and therapeutic significance. Experimental Design: The genetic profiles of 583 advanced differentiated and 196 ATCs generated with targeted next-generation sequencing cancer-associated gene panels MSK-IMPACT and FoundationOne were analyzed. Results: ATC had more genetic alterations per tumor, and pediatric papillary thyroid cancer had fewer genetic alterations per tumor when compared with other thyroid cancer types...
July 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29486779/response-criteria-in-solid-tumors-percist-recist-and-suv-max-in-early-stage-non-small-cell-lung-cancer-patients-treated-with-stereotactic-body-radiotherapy
#3
Cory Pierson, Taras Grinchak, Casey Sokolovic, Brandi Holland, Teresa Parent, Mark Bowling, Hyder Arastu, Paul Walker, Andrew Ju
BACKGROUND: The purpose of this study was to evaluate the prognostic impact of Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) and of pre- and post-treatment maximum Standard Uptake Value (SUVmax ) in regards to survival and tumor control for patients treated for early-stage non-small cell lung cancer (ES-NSCLC) with stereotactic body radiotherapy (SBRT). METHODS: This is a retrospective review of patients with ES-NSCLC treated at our institution using SBRT...
February 27, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/27467575/open-source-drug-discovery-with-the-malaria-box-compound-collection-for-neglected-diseases-and-beyond
#4
Wesley C Van Voorhis, John H Adams, Roberto Adelfio, Vida Ahyong, Myles H Akabas, Pietro Alano, Aintzane Alday, Yesmalie Alemán Resto, Aishah Alsibaee, Ainhoa Alzualde, Katherine T Andrews, Simon V Avery, Vicky M Avery, Lawrence Ayong, Mark Baker, Stephen Baker, Choukri Ben Mamoun, Sangeeta Bhatia, Quentin Bickle, Lotfi Bounaadja, Tana Bowling, Jürgen Bosch, Lauren E Boucher, Fabrice F Boyom, Jose Brea, Marian Brennan, Audrey Burton, Conor R Caffrey, Grazia Camarda, Manuela Carrasquilla, Dee Carter, Maria Belen Cassera, Ken Chih-Chien Cheng, Worathad Chindaudomsate, Anthony Chubb, Beatrice L Colon, Daisy D Colón-López, Yolanda Corbett, Gregory J Crowther, Noemi Cowan, Sarah D'Alessandro, Na Le Dang, Michael Delves, Joseph L DeRisi, Alan Y Du, Sandra Duffy, Shimaa Abd El-Salam El-Sayed, Michael T Ferdig, José A Fernández Robledo, David A Fidock, Isabelle Florent, Patrick V T Fokou, Ani Galstian, Francisco Javier Gamo, Suzanne Gokool, Ben Gold, Todd Golub, Gregory M Goldgof, Rajarshi Guha, W Armand Guiguemde, Nil Gural, R Kiplin Guy, Michael A E Hansen, Kirsten K Hanson, Andrew Hemphill, Rob Hooft van Huijsduijnen, Takaaki Horii, Paul Horrocks, Tyler B Hughes, Christopher Huston, Ikuo Igarashi, Katrin Ingram-Sieber, Maurice A Itoe, Ajit Jadhav, Amornrat Naranuntarat Jensen, Laran T Jensen, Rays H Y Jiang, Annette Kaiser, Jennifer Keiser, Thomas Ketas, Sebastien Kicka, Sunyoung Kim, Kiaran Kirk, Vidya P Kumar, Dennis E Kyle, Maria Jose Lafuente, Scott Landfear, Nathan Lee, Sukjun Lee, Adele M Lehane, Fengwu Li, David Little, Liqiong Liu, Manuel Llinás, Maria I Loza, Aristea Lubar, Leonardo Lucantoni, Isabelle Lucet, Louis Maes, Dalu Mancama, Nuha R Mansour, Sandra March, Sheena McGowan, Iset Medina Vera, Stephan Meister, Luke Mercer, Jordi Mestres, Alvine N Mfopa, Raj N Misra, Seunghyun Moon, John P Moore, Francielly Morais Rodrigues da Costa, Joachim Müller, Arantza Muriana, Stephen Nakazawa Hewitt, Bakela Nare, Carl Nathan, Nathalie Narraidoo, Sujeevi Nawaratna, Kayode K Ojo, Diana Ortiz, Gordana Panic, George Papadatos, Silvia Parapini, Kailash Patra, Ngoc Pham, Sarah Prats, David M Plouffe, Sally-Ann Poulsen, Anupam Pradhan, Celia Quevedo, Ronald J Quinn, Christopher A Rice, Mohamed Abdo Rizk, Andrea Ruecker, Robert St Onge, Rafaela Salgado Ferreira, Jasmeet Samra, Natalie G Robinett, Ulrich Schlecht, Marjorie Schmitt, Filipe Silva Villela, Francesco Silvestrini, Robert Sinden, Dennis A Smith, Thierry Soldati, Andreas Spitzmüller, Serge Maximilian Stamm, David J Sullivan, William Sullivan, Sundari Suresh, Brian M Suzuki, Yo Suzuki, S Joshua Swamidass, Donatella Taramelli, Lauve R Y Tchokouaha, Anjo Theron, David Thomas, Kathryn F Tonissen, Simon Townson, Abhai K Tripathi, Valentin Trofimov, Kenneth O Udenze, Imran Ullah, Cindy Vallieres, Edgar Vigil, Joseph M Vinetz, Phat Voong Vinh, Hoan Vu, Nao-Aki Watanabe, Kate Weatherby, Pamela M White, Andrew F Wilks, Elizabeth A Winzeler, Edward Wojcik, Melanie Wree, Wesley Wu, Naoaki Yokoyama, Paul H A Zollo, Nada Abla, Benjamin Blasco, Jeremy Burrows, Benoît Laleu, Didier Leroy, Thomas Spangenberg, Timothy Wells, Paul A Willis
A major cause of the paucity of new starting points for drug discovery is the lack of interaction between academia and industry. Much of the global resource in biology is present in universities, whereas the focus of medicinal chemistry is still largely within industry. Open source drug discovery, with sharing of information, is clearly a first step towards overcoming this gap. But the interface could especially be bridged through a scale-up of open sharing of physical compounds, which would accelerate the finding of new starting points for drug discovery...
July 2016: PLoS Pathogens
https://www.readbyqxmd.com/read/26292723/targeting-btk-for-the-treatment-of-flt3-itd-mutated-acute-myeloid-leukemia
#5
Genevra Pillinger, Amina Abdul-Aziz, Lyubov Zaitseva, Matthew Lawes, David J MacEwan, Kristian M Bowles, Stuart A Rushworth
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently our group and others have shown that pharmacologic inhibition and genetic knockdown of Bruton's tyrosine kinase (BTK) blocks AML blast proliferation, leukaemic cell adhesion to bone marrow stromal cells as well as migration of AML blasts...
August 21, 2015: Scientific Reports
https://www.readbyqxmd.com/read/26286584/leptin-produced-by-obese-adipose-stromal-stem-cells-enhances-proliferation-and-metastasis-of-estrogen-receptor-positive-breast-cancers
#6
Amy L Strong, Jason F Ohlstein, Brandi A Biagas, Lyndsay V Rhodes, Dorothy T Pei, H Alan Tucker, Claire Llamas, Annie C Bowles, Maria F Dutreil, Shijia Zhang, Jeffrey M Gimble, Matthew E Burow, Bruce A Bunnell
INTRODUCTION: The steady increase in the incidence of obesity among adults has been paralleled with higher levels of obesity-associated breast cancer. While recent studies have suggested that adipose stromal/stem cells (ASCs) isolated from obese women enhance tumorigenicity, the mechanism(s) by which this occurs remains undefined. Evidence suggests that increased adiposity results in increased leptin secretion from adipose tissue, which has been shown to increased cancer cell proliferation...
August 19, 2015: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/26163651/clinical-observations-on-treatment-for-chinese-patients-with-gastrointestinal-stromal-tumors
#7
Zhan-De He, Xin-En Huang, Jian-Nong Zhou
BACKGROUND: To investigate the diagnostic and treatment methods for Chinese patients with gastrointestinal stromal tumor (GIST). MATERIALS AND METHODS: From January 2004 to June 2014, patients diagnosed with primary GIST and treated by a single medical team in the Department of Digestive Disease of XuYi Hospital of Traditional Chinese Medicine were retrospectively recruited. Re-examination and follow-up was conducted regularly and abdominal enhanced CT, blood biochemistry and responses to surgery or imatinib were recorded...
2015: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/26060223/use-of-bevacizumab-in-community-settings-toxicity-profile-and-risk-of-hospitalization-in-patients-with-advanced-non-small-cell-lung-cancer
#8
Nikki M Carroll, Thomas Delate, Alex Menter, Mark C Hornbrook, Lawrence Kushi, Erin J Aiello Bowles, Elizabeth T Loggers, Debra P Ritzwoller
PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. METHODS: Patients with stages IIIB-IV NSCLC age ≥ 21 years diagnosed between 2005 and 2010 who received first-line CP or CPB were identified at four health maintenance organizations (N = 1,109)...
September 2015: Journal of Oncology Practice
https://www.readbyqxmd.com/read/25323587/nrf2-driven-mir-125b1-and-mir-29b1-transcriptional-regulation-controls-a-novel-anti-apoptotic-mirna-regulatory-network-for-aml-survival
#9
N M Shah, L Zaitseva, K M Bowles, D J MacEwan, S A Rushworth
Transcription factor NRF2 is an important regulator of oxidative stress. It is involved in cancer progression, and has abnormal constitutive expression in acute myeloid leukaemia (AML). Posttranscriptional regulation by microRNAs (miRNAs) can affect the malignant phenotype of AML cells. In this study, we identified and characterised NRF2-regulated miRNAs in AML. An miRNA array identified miRNA expression level changes in response to NRF2 knockdown in AML cells. Further analysis of miRNAs concomitantly regulated by knockdown of the NRF2 inhibitor KEAP1 revealed the major candidate NRF2-mediated miRNAs in AML...
April 2015: Cell Death and Differentiation
https://www.readbyqxmd.com/read/24929677/recurrent-read-through-fusion-transcripts-in-breast-cancer
#10
Katherine E Varley, Jason Gertz, Brian S Roberts, Nicholas S Davis, Kevin M Bowling, Marie K Kirby, Amy S Nesmith, Patsy G Oliver, William E Grizzle, Andres Forero, Donald J Buchsbaum, Albert F LoBuglio, Richard M Myers
Read-through fusion transcripts that result from the splicing of two adjacent genes in the same coding orientation are a recently discovered type of chimeric RNA. We sought to determine if read-through fusion transcripts exist in breast cancer. We performed paired-end RNA-seq of 168 breast samples, including 28 breast cancer cell lines, 42 triple negative breast cancer primary tumors, 42 estrogen receptor positive (ER+) breast cancer primary tumors, and 56 non-malignant breast tissue samples. We analyzed the sequencing data to identify breast cancer associated read-through fusion transcripts...
July 2014: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/24633407/comparative-effectiveness-of-adjunctive-bevacizumab-for-advanced-lung-cancer-the-cancer-research-network-experience
#11
COMPARATIVE STUDY
Debra P Ritzwoller, Nikki M Carroll, Thomas Delate, Mark C Hornbrook, Lawrence Kushi, Erin J Aiello Bowles, Elizabeth T Loggers, Alex Menter
INTRODUCTION: Bevacizumab plus carboplatin-paclitaxel (BCP) chemotherapy has Food and Drug Administration approval for advanced nonsquamous, non-small-cell lung cancer based upon improved survival in a clinical trial. However, subgroup analyses of this and other studies have suggested variable results by age and gender. METHODS: Using data from four health maintenance organizations (HMOs) belonging to the Cancer Research Network, 1605 HMO nonsquamous, non-small-cell lung cancer patients aged younger than 21 years, diagnosed 2002-2010, who received carboplatin-paclitaxel (CP), with and without bevacizumab for first-line treatment of stage IIIB/IV disease were identified...
May 2014: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/24086949/afatinib-for-the-treatment-of-patients-with-egfr-positive-non-small-cell-lung-cancer
#12
REVIEW
D W Bowles, A Weickhardt, A Jimeno
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are valuable treatments for EGFR-mutated non-small cell lung cancer (NSCLC). Anti-EGFR antibodies are widely used in the treatment of head and neck squamous cell carcinomas (HNSCC) and in KRAS wild-type colorectal cancer. The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations...
September 2013: Drugs of Today
https://www.readbyqxmd.com/read/24029073/understanding-the-role-of-nrf2-regulated-mirnas-in-human-malignancies
#13
REVIEW
Niraj M Shah, Stuart A Rushworth, Megan Y Murray, Kristian M Bowles, David J MacEwan
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a key transcription factor that regulates the expression of over a hundred cytoprotective and antioxidant genes that provide cellular protection from reactive oxygen species. Chemotherapy resistance in several cancers has been linked to dysregulation of the NRF2 signalling pathway, moreover there is growing evidence that NRF2 may contribute to tumorigenesis. MicroRNA (miRNA) are small non-coding RNA sequences that post-transcriptionally regulate mRNA sequences...
August 2013: Oncotarget
https://www.readbyqxmd.com/read/23788149/tragal-reconstruction-after-tumor-excision
#14
Christopher J Coombs, Frank Lin
The tragus forms a distinct and important landmark in the overall artistic and anatomical landscape of the ear. Despite its small size, it functions to cover and prevent direct access to the ear canal. Aesthetically, it has an important role in defining the morphology of the auricle in 3 dimensions, not only covering the meatus but also casting a shadow into the conchal bowl that gives the impression of depth. Most of the techniques for tragal reconstruction are associated with creation of a tragus in patients with microtia...
February 2015: Annals of Plastic Surgery
https://www.readbyqxmd.com/read/23724410/tivozanib-practical-implications-for-renal-cell-carcinoma-and-other-solid-tumors
#15
REVIEW
E M Berge, D W Bowles, T W Flaig, E T Lam, A Jimeno
Tivozanib is a recently developed, small-molecule tyrosine kinase inhibitor with specific affinity for the vascular endothelial growth factor receptor (VEGFR) family of kinases. Given known relevance of VHL (Von Hippel-Lindau disease tumor suppressor) deregulation in the clear cell variant of renal cell carcinoma, renal cell carcinoma remains an area of interest and subject of recent registration trials with this approach. TIVO-1, a phase III study evaluating tivozanib versus sorafenib in the first-line setting, met its primary endpoint of progression-free survival (11...
May 2013: Drugs of Today
https://www.readbyqxmd.com/read/23598850/patient-reported-discontinuation-of-endocrine-therapy-and-related-adverse-effects-among-women-with-early-stage-breast-cancer
#16
Erin J Aiello Bowles, Denise M Boudreau, Jessica Chubak, Onchee Yu, Monica Fujii, Janet Chestnut, Diana S M Buist
BACKGROUND: Approximately 20% to 50% of women diagnosed with hormone receptor-positive breast cancer discontinue endocrine therapy early; most reports come from automated pharmacy data or small self-report evaluations. We conducted a larger self-report evaluation of endocrine therapy discontinuation associated with patient characteristics and therapy-related adverse effects. METHODS: We surveyed 538 women from a single health plan who were diagnosed with early-stage breast cancer from 2002 to 2008 and received endocrine therapy...
November 2012: Journal of Oncology Practice
https://www.readbyqxmd.com/read/23022316/patterns-and-predictors-of-first-line-chemotherapy-use-among-adults-with-advanced-non-small-cell-lung-cancer-in-the-cancer-research-network
#17
Debra P Ritzwoller, Nikki M Carroll, Thomas Delate, Mark C Hornbrook, Lawrence Kushi, Erin J Aiello Bowles, Jared M Freml, Karl Huang, Elizabeth T Loggers
BACKGROUND: Relatively low rates of chemotherapy receipt have been observed in older patients diagnosed with advanced non-small cell lung cancer (NSCLC) in SEER-Medicare-based studies. However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib. METHODS: A cohort of 6614 stage IIIB/IV NSCLC patients aged ≥ 21 years diagnosed between 2000 and 2007 was identified at four HMOs that participate in the Cancer Research Network (CRN)...
December 2012: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/22877636/discovery-of-xl888-a-novel-tropane-derived-small-molecule-inhibitor-of-hsp90
#18
Joerg Bussenius, Charles M Blazey, Naing Aay, Neel K Anand, Arlyn Arcalas, TaeGon Baik, Owen J Bowles, Chris A Buhr, Simona Costanzo, Jeffrey K Curtis, Steven C DeFina, Larisa Dubenko, Timothy S Heuer, Ping Huang, Christopher Jaeger, Anagha Joshi, Abigail R Kennedy, Angie I Kim, Katherine Lara, Jae Lee, Jonathan Li, Julie C Lougheed, Sunghoon Ma, Shiva Malek, Jean-Claire L Manalo, Jean-Francois Martini, Garth McGrath, Monique Nicoll, John M Nuss, Michael Pack, Csaba J Peto, Tsze H Tsang, Longcheng Wang, Scott W Womble, Michael Yakes, Wentao Zhang, Kenneth D Rice
With structural guidance, tropane-derived HTS hits were modified to optimize for HSP90 inhibition and a desirable in vivo profile. Through an iterative SAR development process 12i (XL888) was discovered and shown to reduce HSP90 client protein content in PD studies. Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens.
September 1, 2012: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/22844657/vismodegib-in-basal-cell-carcinoma
#19
REVIEW
R N Amaria, D W Bowles, K D Lewis, A Jimeno
Vismodegib is a novel, small-molecule inhibitor of smoothened, a key component of the hedgehog signaling pathway. Increased hedgehog pathway signaling is critical in the development of hereditary and spontaneous basal cell carcinomas of the skin, and has been implicated in the development of a number of other tumors. In preclinical models, vismodegib demonstrated potent antitumor activity in hedgehog-dependent tumors, particularly basal cell carcinomas. Clinically, phase I and II studies showed dramatic anticancer activity in patients with advanced basal cell carcinomas...
July 2012: Drugs of Today
https://www.readbyqxmd.com/read/22693357/a-multicenter-phase-i-trial-of-px-866-an-oral-irreversible-phosphatidylinositol-3-kinase-inhibitor-in-patients-with-advanced-solid-tumors
#20
MULTICENTER STUDY
David S Hong, Daniel W Bowles, Gerald S Falchook, Wells A Messersmith, Goldy C George, Cindy L O'Bryant, Alex C H Vo, Kevin Klucher, Roy S Herbst, S Gail Eckhardt, Scott Peterson, Diana F Hausman, Razelle Kurzrock, Antonio Jimeno
PURPOSE: The objectives of the study were to evaluate the maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity of PX-866 in patients with incurable cancers. EXPERIMENTAL DESIGN: This was a phase I, open-label, dose-escalation study. Drug was administered orally once per day either on an intermittent (arm 1; days 1-5 and 8-12 of a 28-day cycle) or continuous (arm 2; days 1-28 of a 28-day cycle) schedule. Additional patients were treated at the arm 2 MTD in a food effects substudy...
August 1, 2012: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
163399
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"